通过 GLP-1 受体激动剂和 SGLT2 抑制剂调节心外膜脂肪来降低心血管风险。
Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat.
机构信息
Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Miller School of Medicine, University of Miami, 1400 NW 10th Ave, Dominion Tower suite 805-807, Miami, FL, 33136, USA.
Endocrinology and Diabetes, Department of Clinical Medicine, Public Health, Life and Environmental Sciences (MeSVA), University of L'Aquila, L'Aquila, Italy.
出版信息
J Endocrinol Invest. 2022 Mar;45(3):489-495. doi: 10.1007/s40618-021-01687-1. Epub 2021 Oct 13.
Epicardial adipose tissue is a novel cardiovascular risk factor. It plays a role in the progression of coronary artery disease, heart failure and atrial fibrillation. Given its rapid metabolism, clinical measurability, and modifiability, epicardial fat works well as therapeutic target of drugs modulating the adipose tissue. Epicardial fat responds to glucagon-like peptide 1 receptor agonists (GLP1A) and sodium glucose co-transporter 2 inhibitors (SGLT2i). GLP-1A and SGLT2i provide weight loss and cardiovascular protective effects beyond diabetes control, as recently demonstrated. The potential of modulating the epicardial fat morphology and genetic profile with targeted pharmacological agents can open new avenues in the pharmacotherapy of diabetes and obesity, with particular focus on cardiovascular risk reduction.
心外膜脂肪组织是一种新的心血管危险因素。它在心 绞痛、心力衰竭和心房颤动的进展中发挥作用。鉴于其 快速代谢、临床可测量性和可修饰性，心外膜脂肪作为调 节脂肪组织的药物的治疗靶点效果良好。心外膜脂肪对胰 高血糖素样肽 1 受体激动剂 (GLP1A) 和钠-葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i) 有反应。GLP-1A 和 SGLT2i 在控制糖尿病之外提供体重减轻和心血管保护作用，最近已经证明。通过靶向药物来调节心外膜脂肪形态和遗传特征的潜力，可以为糖尿病和肥胖症的药物治疗开辟新途径，特别关注心血管风险降低。
Zotero 插件